Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
2.880
-0.220 (-7.10%)
At close: Jan 2, 2026, 4:00 PM EST
2.937
+0.057 (1.99%)
Pre-market: Jan 5, 2026, 8:00 AM EST
Gossamer Bio Revenue
Gossamer Bio had revenue of $13.29M in the quarter ending September 30, 2025, with 40.23% growth. This brings the company's revenue in the last twelve months to $44.05M, down -58.17% year-over-year. In the year 2024, Gossamer Bio had annual revenue of $114.70M.
Revenue (ttm)
$44.05M
Revenue Growth
-58.17%
P/S Ratio
14.85
Revenue / Employee
$303,800
Employees
145
Market Cap
666.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 114.70M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GOSS News
- 26 days ago - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Gossamer Bio to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 3 months ago - Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital - PRNewsWire
- 3 months ago - Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension - Business Wire
- 3 months ago - Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 - Business Wire
- 4 months ago - Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout - Seeking Alpha
- 4 months ago - Gossamer Bio to Present at Upcoming Investor Conferences - Business Wire